Ovarian Cancer accounts for 33% of gynecological malignancies but causes 55% of gynecologic cancer deaths. Eighty-five to ninety percent of ovarian cancers of the epithelial cell type. The overall theme of this Program project (renewal of CA52477) is to: 1) perform histochemical, biochemical and molecular studies to improve our understanding of the biology of epithelial ovarian cancer, 2) conduct clinical trials in newly diagnosed and persistent/recurrent ovarian cancer using novel chemotherapeutic approaches, and 3) investigate the efficacy the efficacy and safety of immunotherapy using radiolabeled monoclonal antibodies and polyvalent vaccines. The general theme will be achieved through three separate projects with the support of four cores in a Program Project that has been designed to maximize existing collaborations and to develop new collaborations. The effective multi-disciplinary collaboration addressing a single disease will allowed shared resources and will stimulate the development and integration of ideas from different areas of expertise in such a way that the whole will be greater than the sum of the parts.
The specific aim of this Program Project in epithelial ovarian cancer is the confirmation of the following hypotheses: 1) intensification of therapy (surgical and chemotherapeutic) can improve survival in a select group of ovarian cancer patients. 2) New types of therapy are necessary for patients who do not achieve a complete response to conventional therapy. 3) Improvements in salvage therapy can be achieved. 4) Immunotherapy using radio-labeled monoclonal antibodies or polyvalent vaccines may be effective adjuvant therapy for patients with minimal residual disease following primary therapy. 5) Analysis of antigenic and molecular markers for epithelial ovarian cancer can improve our understanding of the development of ovarian cancer. 6) Further analyses of ovarian cancer antigens will allow for the development of better antibodies and vaccines for modification of existing antibodies to improve the diagnosis and treatment of ovarian cancer. The superb resources and active support of Memorial Sloan-Kettering Cancer Center provides an ideal setting for this Program Project. The combined expertise of the investigators involved provides ample experience and knowledge to carry out this Project successfully.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-11
Application #
6375876
Study Section
Subcommittee G - Education (NCI)
Program Officer
Wu, Roy S
Project Start
1991-04-15
Project End
2003-07-31
Budget Start
2001-08-15
Budget End
2002-07-31
Support Year
11
Fiscal Year
2001
Total Cost
$1,703,177
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20
Hyman, David M; Long, Kara C; Tanner, Edward J et al. (2012) Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. Gynecol Oncol 126:224-8
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24

Showing the most recent 10 out of 109 publications